Michael Nally

Nally spent 18 years at Merck, rising to the rank of president of the vaccine business in 2016 before going on to spend his final two years at the company as chief marketing officer, human health. Over those two years, Nally led Merck's global marketing, commercialization model and long-term growth strategy. Merck hired Nally as a senior financial analyst in 2003.

At Flagship, Nally occupies a hybrid role. Nally contributes to the Flagship leadership team while also running one of its biotechs, Generate Biomedicines.